OBJECTIVES §The objective of this retrospective real-world evidence (RWE) study was to examine resource use and costs in ITP patients treated with eltrombopag (EPAG) or romiplostim (ROMI).
METHODS
DATA SOURCES §TriNetX, a syndicated network of electronic medical records (EMR) from 26 US hospital institutions treating over 27 million patients, was searched §TRiNetX EMR include: (Lin, et al. 2017) §After excluding confounders, patients were divided into mutually exclusive cohorts treated with EPAG or ROMI RESOURCE USE AND COSTS §A total of four years of patient data were analyzed via TriNetX §The rates of rescue therapy use, adverse events (AEs) and use of routine health care were collected over 12 months following treatment initiation §The rates of platelet transfusion, IVIg, and IV methylprednisolone were recorded as rescue therapy use §The list of AEs of interest was constructed based on the FDA labels for EPAG and ROMI §The rates of office visits, ER visits, and hospitalizations were collected as routine healthcare use UNIT COSTS §Total treatment costs for EPAG and ROMI per patient per year were calculated using drug costs per week and administration costs per week §Unit costs obtained from various public sources were applied to the rates of resource use to calculate the costs per patient per year for each resource §Annual total costs per ITP patient receiving EPAG or ROMI as second-line were calculated by adding total treatment costs, total costs for rescue therapies, total AE costs, and costs for routine healthcare use §95% confidence intervals (CIs) were calculated for each resource use, except the drug costs, and used to calculate the CIs for the total costs.
CONCLUSIONS §This retrospective RWE study reports annual economic burden of ITP treatment. Total annual costs of treatment were substantially lower for EPAG vs. ROMI.
RESULTS
TREATMENT COSTS PER YEAR §A total of 1,030 patients were identified after cohort matching: Among them, 650 and 380 patients received EPAG and ROMI as second-line therapy, respectively. §Total treatment costs per patient per year were calculated based on unit costs for drugs and administration §Treatment and administration costs were lower for the EPAG cohort compared to the ROMI cohort RESCUE MEDICATION COSTS §ROMI cohort had higher rates of rescue medication use over 12 months following drug initiation compared to EPAG §ROMI cohort showed higher total costs for rescue therapies per patient per year compared to EPAG
EPAG (N=650) ROMI (N=380)

ADVERSE EVENT COSTS
§ROMI cohort showed higher rates of AEs as compared to EPAG with the exception of diarrhea and upper respiratory tract infections, leading to higher overall AErelated costs.
ROUTINE HEALTHCARE COSTS §Although EPAG cohort had higher rates of office visits and emergency department visits as compared to ROMI; the ROMI cohort showed higher rates of diagnostic tests and hospitalizations versus EPAG. §Total health care costs were higher for ROMI as compared to EPAG, mainly driven by hospitalization costs.
TOTAL COSTS §Total annual treatment costs per patient were $71,632 for EPAG and $98,432 for ROMI §ROMI cohort showed higher costs for all four sub categories: treatment and administration, rescue medications, adverse events, and health care costs §Treatment costs accounted for approximate 87% and 86% of the total cost for EPAG and ROMI, respectively LIMITATIONS §Study limitations include reliance on electronic medical records with limited longitudinal data.
